Mednet Logo
HomeGastroenterology
Gastroenterology

Gastroenterology

Expert perspectives on IBD, liver disease, motility disorders, and GI diagnostic and therapeutic procedures.

Recent Discussions

What is your treatment algorithm for management of retroperitoneal fibrosis that does not respond to high-dose glucocorticoids?

5
1 Answers

Mednet Member
Mednet Member
Rheumatology · MUSC Health

There are a number of caveats to this. Is the retroperitoneal fibrosis biopsy-proven and/or IgG4 disease ruled out? If a case is refractory, I first question whether the diagnosis is correct and will often biopsy in this situation with more than an FNA biopsy. The second question is how long have t...

How long do you typically treat patients with phentermine for weight loss and what clinical markers do you follow?

1
2 Answers

Mednet Member
Mednet Member
Endocrinology · Tufts Medical Center Physicians Organization

Phentermine has been available since 1959 and remains an affordable and effective medication option added to a full lifestyle-based weight management plan. In people who are generally healthy and without contraindications to the medication, I have had patients used in at least intermittently for sev...

How do you diagnose and manage suspected opioid-induced esophageal dysfunction?

1
2 Answers

Mednet Member
Mednet Member
Gastroenterology · University of South Florida

Patients with opioid-induced esophageal dysfunction have symptoms of most often, chest pain or dysphagia, with manometric findings of EGJ outflow obstruction, type 3 achalasia, or esophageal spasm/hypercontractile/jackhammer esophagus. When manometry suggests EGJOO or type 3 achalasia, in our practi...

When would you phlebotomize patients with secondary hemochromatosis, such as due to NAFLD/cirrhosis?

3
1 Answers

Mednet Member
Mednet Member
Hematology · Weill Cornell Medical College and Houston Methodist Hospital

My simple answer is “rarely, if ever” (but it can get much more complicated). Related to hepcidin changes, patients with chronic liver disease frequently have elevated serum ferritin and transferrin saturation, more so with alcoholic liver disease and non-alcoholic fatty liver disease. It is far fro...

Which patients, if any, do you revert back to ultrasound screening for HCC after prior diagnosis/definitive treatment of HCC?

1
1 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Wisconsin

I don't revert back to U/S for these patients ever. It's not dissimilar from colorectal cancer screening - once you have colon cancer, it's not appropriate to use iFOBT or stool DNA screening anymore - it's lifelong colonoscopy screening. Likewise, for HCC, I continue to use AFP plus cross-sectional...

What are your vaccine recommendations while patients are on biologics?

5
2 Answers

Mednet Member
Mednet Member
Dermatology · Solano Dermatology Associates

Live vaccines are best completed at least a month before initiation of biologics when these are appropriate (e.g., MMR, chickenpox, yellow fever). The data on non-live vaccines is limited. I personally think that some degree of protection is better than none. I will not interrupt biological therapy ...

What are your top takeaways from AASLD 2025?

1
1 Answers

Mednet Member
Mednet Member
Hepatology · University of Wisconsin

A lot of interest and research in new steatotic liver disease classifications (MASLD, Met-ALD, and ALD) with interesting abstracts about assessment of alcohol use (PETH, AUDIT-C) and the number of metabolic comorbidities that occur in these classifications. Very robust clinical research workshop, as...

Which patient characteristics increase the diagnostic yield of A1AT level testing in newly diagnosed cirrhosis, and when should phenotyping be performed in addition to measuring levels?

1
1 Answers

Mednet Member
Mednet Member
Hepatology · Johns Hopkins Medicine

We have issues with getting phenotypes paid for by Medicare and Medicaid, so I often send a level first. If the level is below 80 mg/dL, then I send the phenotype. Also, concern is raised in patients with FH of cirrhosis or emphysema, or the patient does not have other obvious risk factors for cirrh...

What new or emerging therapies for autoimmune gastritis are available beyond iron and vitamin B12 replacement?

2
1 Answers

Mednet Member
Mednet Member
Gastroenterology · Washington University School Of Medicine Gastroenterology

Though we recognize autoimmune gastritis (AIG) as an autoimmune disease that targets antigens expressed on parietal cells of the stomach, there are currently no effective treatments to reduce gastric inflammation and to prevent parietal cell loss. Back in the 1960s, small studies looked at the role ...

For remote liver transplant recipients back under the care of a community gastroenterologist (or PCP), what should be the approach to new liver enzyme elevations?

1
1 Answers

Mednet Member
Mednet Member
Hepatology · Northwestern Memorial Hospital

Elevated liver enzymes in post-transplant patients who live far from their transplant center are a common challenging issue. Many factors will influence your recommendation to the local physician: height of enzyme elevation, cholestatic, hepatitic, or mixed profile, and associated symptoms (pain, fe...